Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NeXstar, Fujisawa USA Inc. regulatory update

The FDA extended marketing approval for NXTR's AmBisome lipid amphotericin B

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE